Investigating how UBR5 contributes to cancer growth and immune response
UBR5's mechanisms of action in tumorigenesis and immunoregulation
['FUNDING_R01'] · WEILL MEDICAL COLL OF CORNELL UNIV · NIH-11032883
This study is looking at how a gene called UBR5 affects the growth and spread of aggressive breast and ovarian cancers, and how it might help these tumors avoid the immune system, with the goal of finding new treatment options for patients.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WEILL MEDICAL COLL OF CORNELL UNIV (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-11032883 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the role of the UBR5 gene in various aggressive cancers, particularly breast and ovarian cancer. It examines how UBR5 amplifications and overexpression affect tumor growth and metastasis, as well as the immune system's response to these tumors. By conducting both laboratory experiments and clinical analyses, the research aims to uncover the mechanisms by which UBR5 influences cancer progression and immune evasion, potentially leading to new therapeutic strategies for patients with these cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients diagnosed with aggressive breast or ovarian cancers, particularly those with genetic alterations in the UBR5 gene.
Not a fit: Patients with early-stage or less aggressive forms of breast or ovarian cancer may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of novel therapies that improve survival rates for patients with aggressive breast and ovarian cancers.
How similar studies have performed: Previous research has shown promising results in targeting similar oncogenes and their pathways, indicating potential for success in this area.
Where this research is happening
NEW YORK, UNITED STATES
- WEILL MEDICAL COLL OF CORNELL UNIV — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MA, XIAOJING — WEILL MEDICAL COLL OF CORNELL UNIV
- Study coordinator: MA, XIAOJING
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Breast Cancer